The relationship between oral contraceptives and breast cancer continues to receive widespread attention, particularly given the substantial incidence of this disease and the high prevalence of oral contraceptive use. Endogenous hormones and reproductive factors have been implicated in the aetiology of breast cancer (Kelsey & Hildreth, 1983; Henderson et al., 1982) , focusing concern on potential adverse effects of exogenous hormones.
The relationship between oral contraceptives and breast cancer continues to receive widespread attention, particularly given the substantial incidence of this disease and the high prevalence of oral contraceptive use. Endogenous hormones and reproductive factors have been implicated in the aetiology of breast cancer (Kelsey & Hildreth, 1983; Henderson et al., 1982) , focusing concern on potential adverse effects of exogenous hormones.
Epidemiological studies have consistently shown no overall relationship between the use of oral contraceptives and the risk of developing breast cancer (Trapido, 1981; Kay, 1981; Kelsey et al., 1981; Brinton et al., 1982; CDC, 1983; Vessey et al., 1983; Henneken et al., 1984; Rosenberg et al., 1984; Sattin et al., 1986; LaVecchia et al., 1986; Lipnick et al., 1986; Paul et al., 1986; Schlesselman et al., 1988) , although some investigators have reported risk elevations among certain subgroups of exposed women. In particular, there is evidence that oral contraceptives may alter the risk of breast cancer in women with a family history of breast cancer (Black et al., 1980; Brinton et al., 1982) , women with prior benign breast lesions (Fasal & Paffenbarger, 1975 , 1977 Lees et al., 1978; Brinton et al., 1982; Janerich et al., 1983) , young women with extended periods of use before a first live birth (Paffenbarger et al., 1977 (Paffenbarger et al., , 1980 Pike et al., 1981; Harris et al., 1982; McPherson et al., 1983 McPherson et al., , 1987 Meirik et al., 1986) or before age 25 (Pike et al., 1983; Olsson et al., 1985; Meirik et al., 1986) , women under 35 years of age at diagnosis (Kay & Hannaford, 1988) and older women who used oral contraceptives around the perimenopausal period (Vessey et al., 1979; Jick et al., 1980; Paffenbarger et al., 1980; Kay, 1981; Brinton et al., 1982; Henneken et al., 1984) . These relationships, however, have not been consistently found (Vessey et al., 1981 (Vessey et al., , 1982 Stadel et al., 1985; Miller et al., 1986; Prentice & Thomas, 1987; Schlesselman et al., 1988) .
Another important unanswered question is whether the clinical stage of disease at breast cancer diagnosis varies according to patterns of oral contraceptive use. Vessey et al. (1979) found that users of oral contraceptives had less advanced tumours at presentation than non-users, but it is unclear whether this effect differed according to duration of use. This inverse relationship between stage and oral contraceptive use was interpreted initially as evidence for Correspondence: J.L. Stanford. Received 2 February 1989, and in revised form, 14 April 1989. possible surveillance bias, e.g. oral contraceptive users, who are more likely than non-users to be under medical surveillance, may have their tumours diagnosed at an earlier stage. After further analyses, the authors reported that the observed inverse relationship may be attributed to oral contraceptives exerting favourable effects on tumour growth and spread .
The present analysis was designed to address the relationship between oral contraceptive use and breast cancer risk in an expanded case-control study. Initial results from this study, based on the first 4 years of a mammography screening programme, were published in 1982 (Brinton et al., 1982) . Since that time, the study was expanded to include cases identified through the final 3 years of the screening programme. In addition, oral contraceptive effects were evaluated according to the stage of disease at breast cancer diagnosis.
Materials and methods
Study subjects were women enrolled in a nationwide breast cancer screening programme, the Breast Cancer Detection Demonstration Project (BCDDP), jointly sponsored by the National Cancer Institute and the American Cancer Society. Details of the study population and methodology have been described elsewhere (Brinton et al., 1983 (Brinton et al., , 1986a . Briefly, participants in the BCDDP were recruited between 1973 and 1975, and followed through 1980 for a 5-year programme of annual breast examinations. Cases for the present analysis were all women who were diagnosed with breast cancer during the screening period. The initial phase of the study was conducted among women diagnosed with primary breast cancer during July 1973 to May 1977. A 3-year extension of the study included cases diagnosed through November 1980. Control subjects were also women enrolled in the screening programme, but who were not recommended for a breast biopsy over the course of the project. Controls were randomly chosen from a large pool of eligible women and frequency-stratified to cancer cases on age (within 5 years), race, screening centre, year of entry into the screening programme and duration of participation in the project.
Uniformly trained study personnel conducted structured home interviews for all study subjects. Possible effect modification of the association between oral contraceptives and breast cancer was also evaluated by multivariate models (Breslow & Day, 1980) . Statistical significance (P< 0.05) of possible interaction effects was determined by computing the difference in log-likelihood estimates between models excluding and including the interaction term. Two-tailed tests for trend in the logistic analyses were obtained by treating categories of the exposure variable as interval data. Because the study employed a matched design, matched analyses were also undertaken (Lubin, 1981) , and produced results similar to the unmatched analyses chosen for presentation.
Results
Rates of oral contraceptive use among study subjects varied by age, but none of the age-specific risk estimates were significantly different from unity (Table T) . Women 40-44 years of age had the highest risk estimate (RR= 1.4). The overall age-adjusted relative risk estimate for the association between ever use of oral contraceptives and breast cancer was 1.0 (95% CI 0.9-1.2). (Jick et al., 1980; Pike et al., 1981; Harris et al., 1982; Meirik et al., 1986; McPherson et al., 1987) . We thus attempted to examine these issues further. Because of the age distribution of our subjects, we had no women who had used oral contraceptives for extended periods -of time before age 25 (Table III) . There was no evidence that oral contraceptives used for less than 5 years before age 25 were associated with increased risk (RR=0.96, 95% CI 0.6-1.7). The risk of breast cancer associated with use after age 25 was also not elevated, with the exception of a slight increase in risk for women who used oral contraceptives for 5-9 years (RR= 1.4, 95% CI 1.0-1.8). A similar analysis of the duration of oral contraceptive use before and after a first live birth failed to demonstrate any significant relationships.
Another issue raised by previous studies is whether oral contraceptive use during perimenopausal years changes a women's risk for breast cancer (Vessey et al., 1979; Jick et al., 1980; Kay, 1981; Brinton et al., 1982; Henneken et al., 1984) . Oral contraceptive use around the time of menopause may extend a woman's menstrual cycles, resulting in unusually high levels of circulating oestrogens and progestogens when these hormones would normally be at lower levels due to the onset of menopause. We estimated risk according to the duration of oral contraceptive use in premenopausal and post-menopausal women, focusing on exposures before and after age 40 (Table IV) Because of the potential interaction between oral contraceptives and prior benign disease, the temporal relation of oral contraceptive use to breast biopsy was considered (Table VI) nodes revealed no significant associations in relation to short-term (<5 years) use, or in relation to long-term (> 5 years) use in women with no involved nodes (RR=1.0) or an unknown number of involved nodes (RR=0.74). Nonsignificant increases in risk were observed for users of 5 or more years duration who had one to three positive nodes (RR= 1.7) and those with four or more positive nodes (RR= 1.9); these elevations in risk were further examined by stratification on stage of disease. For long-term users with one to three positive nodes, risk was higher in those with small invasive (RR=3.1) compared to large invasive (RR=1.5) tumours. Among women with four or more positive nodes, risk in relation to long-term oral contraceptive use was higher in those with large invasive (RR= 1.8) compared to small invasive (RR= 1.3) cancers. Additional analyses examined oral contraceptive effects on the risk of in situ and invasive cancer according to other risk factors (Table VIII) . There was no evidence that risks in relation to oral contraceptive use differed for either in situ or invasive cancers by a family history of breast cancer in a first degree relative, or age at first live birth. Oral contraceptives did exert an adverse effect on the risk for invasive cancer in women with two or more biopsies for benign lesions (RR = 2.4).
Discussion
The results of the present study, based on a population of older women, provide further evidence against an association between ever use of oral contraceptives and risk of breast cancer. There were no overall elevations in risk according to the duration of oral contraceptive use, or time intervals since first or last use. Oral contraceptive effects also did not interact with a family history of breast cancer, age at first live birth, use of menopausal oestrogens or obesity. In addition, oral contraceptive use before age 25, before a first birth or during the perimenopausal period did not appear to influence substantially the risk of breast cancer, although there were too few exposed women in some subgroups to assess risk adequately. However, risk estimates for breast cancer in relation to oral contraceptive use did vary according to previous biopsies for benign breast disease and stage of breast cancer at the time of diagnosis.
Previous reports of an adverse effect of oral contraceptives in young women with extended durations of use before age 25 or a first live birth (Paffenbarger, 1977; Pike et al., 1981 Pike et al., , 1983 Harris et al., 1982; McPherson et al., 1983 McPherson et al., , 1987 Olsson et al., 1985; Meirik et al., 1986) prompted us to examine this issue. Since no women in the present study had used oral contraceptives for extended periods of time at an early age, we were unable to estimate risks in relation to such use. However, based on small numbers, oral contraceptive use lasting less than 5 years before age 25 or first birth was not associated with risk.
In contrast to earlier reports (Vessey et al., 1979; Jick et al., 1980; Paffenbarger et al., 1980; Brinton et al., 1982; Henneken et al., 1984) , we found no evidence that oral contraceptive use around the time of menopause increased the risk of breast cancer. Premenopausal women who took oral contraceptives for extended periods of time after age 40 were not found to be at high risk. Use of oral contraceptives during the perimenopause might be expected to enhance the risk of breast cancer by prolonging menstrual cycling, maintaining higher levels of oestrogens and progestogens at a time when these hormones would be circulating at lower levels due to changes in ovarian function associated with the menopause.
It is noteworthy that we found no evidence of significant effect modification of oral contraceptives by other breast cancer risk factors. These results fail to confirm earlier studies that found certain high-risk groups of users, specifically those with a family history of breast cancer (Black et al., 1980; Brinton et al., 1982 ). An earlier report based on a subset of this study population showed elevated risks for users of oral contraceptives who had a positive history of breast cancer in a sister(s) (Brinton et al., 1982) . This discrepancy with the present results may be due to the smaller numbers of exposed women included in the initial report, and to the decision to limit this analysis of sister(s) with breast cancer to women who reported having at least one sister.
We did observe elevations in risk among oral contraceptive users with two or more previous biopsies for benign breast lesions. Within the context of the BCDDP, women with two or more breast biopsies are thought to represent the group that is more similar to benign breast disease defined in other studies. In an earlier publication based on participants of the BCDDP, Brinton et al. (1979) noted the high prevalence of breast biopsy in this screening population and that a previous history of one biopsy was not a risk factor for breast cancer (RR=0.83), whereas a history of more than one biopsy was associated with an increased risk (RR=2.1). These present findings are somewhat surprising since oral contraceptives protect against benign breast disease. It is possible that the benign lesions arising in the context of exposure to oral contraceptives which protect against such lesions represent unusual types that are more strongly related to breast cancer risk.
The relationship between oral contraceptive use and the stage of breast cancer at the time of diagnosis was of primary interest in the present study. Previous studies reported less advanced disease in users, and ascribed the finding to either surveillance bias from early detection of tumours in women taking oral contraceptives or favourable biological effects of oral contraceptives on tumour growth (Vessey et al., 1979 Ravnihar et al., 1988) . Skegg (1988) recently reviewed the potential influence of surveillance bias on results of studies of breast cancer in relation to oral contraceptives, and noted that such bias could produce a spuriously elevated risk. This would be particularly true if oral contraceptive users more frequently practice breast self-examination or have more routine screening by medical personnel (palpation and mammography), resulting in the identification of the breast cancer at an earlier stage.
In addition to the potential influence of surveillance bias, there is some suggestion that oral contraceptives may exert favourable biological activities on tumour growth and spread. Studies of prognosis reported an apparent survival advantage in breast cancer patients with a history of oral contraceptive use (Spencer et al., 1978; Vessey et al., 1979; Matthews et al., 1981; Rosner & Lane, 1986) , although adjustment for the stage of disease at diagnosis reduced the beneficial effect in two studies (Vessey et al., 1979; Rosner & Lane, 1986) . A third study of oral contraceptives and survival in breast cancer patients failed to support the notion that oral contraceptives confer a positive influence on breast tumour growth (Millard et al., 1987) . Further, data from a recent cohort study showed similar 5-year survival rates in oral contraceptive users and controls (Kay & Hannaford, 1988) .
Our findings contrast with prior reports (Vessey et al., 1979 (Vessey et al., , 1981 Ravnihar et al., 1988) that noted a higher proportion of oral contraceptive users in women with early stage disease. Although no significant relationships were observed between ever use of oral contraceptives and the clinical stage of disease at diagnosis, dissimilar risk patterns were noted for users of 5 or more years duration among women with in situ compared to invasive disease. In the present study, oral contraceptive use was associated with a reduction in risk for in situ disease in both recent users and those who discontinued use > 1 year before diagnosis, but a 40-50% increase in risk for invasive cancer. Since all women included in the present study were identified through a breast cancer screening programme, it is less likely that our results can be explained by surveillance bias. In fact, the lower risk estimates observed for in situ breast cancer in relation to oral contraceptive use argue against an 'early detection' bias (Skegg, 1988) . The results of this study must await confirmation, but suggest that oral contraceptive effects may vary by stage of disease. However, since results based on subgroup analyses may be due .to chance alone, these findings should be interpreted cautiously. Few prior studies have analysed breast cancer risk factors according to stage of disease. Brinton et al. (1983) found generally similar risk factor profiles for women with benign breast disease and those with in situ breast cancer; however, different predictors of risk were observed for in situ compared to invasive disease. Our findings regarding oral contraceptive effects by pathological stage of disease support the notion that in situ and invasive tumours may as groups be aetiologically dissimilar.
In summary, our results provide further evidence against a causal relationship between ever use of oral contraceptives and breast cancer. Women with several prior biopsied benign breast lesions who use oral contraceptives, however, may experience some elevation in risk. The finding that oral contraceptive use of 5 or more years duration is associated with reduced risk for in situ disease, but increased risk for invasive cancer must await confirmation. Based on these results, additional studies of oral contraceptives in relation to the stage of breast cancer at the time of diagnosis are needed. Such future studies should account for possible sources of surveillance bias that may inflitence investigations of oral contraceptives and breast cancer.
